Glucose Control In Hematopoetic Stem Cell Transplant
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Intensive Control of Glucose Effects on Mortality in Allogenic Hematopoietic Stem Cell Transplant (HSCT)
研究概览
简要总结
To determine whether intensive glucose control results in improved mortality and reduced hospital stay length by performing a randomized trial of intensive glucose management (blood glucose goal 110 mg/dl) using continuous IV insulin and glucose vs. non-intensive glucose management (goal 200 mg/dl)
详细描述
TO determine whether there are fewer infections, days without a fever, days on antibiotics given for an infection and time to marrow engraftment are improved by intensive glucose management; and to determine whether there is evidence of a reduction in measures of inflammation in patients randomized to intensive glucose management and whether reduction of inflammation is associated with outcome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients older than 18
- •Must meet standard criteria for HSCT
- •If patient is known diabetic at admit the may be maintained on home sulfonylurea and insulin if randomized to the conventional arm
排除标准
- •If on intensive arm patient must stop all oral hyperglycemic meds
研究组 & 干预措施
Arm 1
Regular Sliding Scale Insulin administration for hyperglycemia
干预措施: Regular Insulin (Drug)
Arm 2
MiniMed Paradigm monitoring device for hyperglycemia
干预措施: Deployment of the MiniMed Paradigm monitoring device (Device)
结局指标
主要结局
Intensive Control of Glucose Effects on Mortality in Allogenic Hematopoietic Stem Cell Transplant (HSCT)
时间窗: 100 days
次要结局
- Reduction of Infection(About 100 days)
- Reduced Length of In-hospital Stay(About 100 days)